All filters
Slidesets
What is the Virological support for reduced drug regimens? | Daniel Kuritzkes, MD
Presented at:
Global HIV Clinical Forum 2018
Slidesets
What is the Pharmacological support for reduce drug regimens? | David Back, PhD
Presented at:
Global HIV Clinical Forum 2018
Slidesets
Expanding Integrase Inhibitors in the rest of Europe | Miłosz Parczewski, MD, PhD
Presented at:
Global HIV Clinical Forum 2018
Slidesets
Implication of the resent Dolutegravir data | Rebecca Zash, MD
Presented at:
Global HIV Clinical Forum 2018
Slidesets
Clinical case: Integrase Inhibitors in Africa | Julia Turner, MD
Presented at:
Global HIV Clinical Forum 2018
Slidesets
Designing e-health interventions for HIV care | Guido van den Berk, MD, PhD
Presented at:
Global HIV Clinical Forum 2018
Slidesets
State of the ART: Integrase Inhibitors (clinical overview) | Mauro Schechter, MD, PhD
Presented at:
Global HIV Clinical Forum 2018
Slidesets
One pill a day?: Integration novel delivery systems into routine care | Terry Blaschke, MD
Presented at:
Global HIV Clinical Forum 2018
Slidesets
What is the Clinical support for reduce drug regimens? | Anton Pozniak, MD, FRCP
Presented at:
Global HIV Clinical Forum 2018
Meeting
Global HIV Clinical Forum 2018
Slidesets
Early treatment and clinical outcomes – does early ART make a difference?- Louise Kuhn, PhD
Presented at:
International Workshop on HIV & Pediatrics 2018
Slidesets
Opening Words- Lynne Mofenson, MD
Presented at:
International Workshop on HIV & Pediatrics 2018
Slidesets
Controllers: post-treatment vs elite controllers – what do we know?- Phillip Goulder, MA, FRCPCH, DPhil, FMedSc
Presented at:
International Workshop on HIV & Pediatrics 2018
Slidesets
HIV vaccines and broadly neutralizing monoclonal antibody - role in the cure agenda- Sandhya Vasan, MD
Presented at:
International Workshop on HIV & Pediatrics 2018
Slidesets
Debate: All children should be switched to dolutegravir-based ART regimens
Presented at:
International Workshop on HIV & Pediatrics 2018
Slidesets
Debate: All children should be switched to dolutegravir-based ART regimens CON- Nandita Sugandhi
Presented at:
International Workshop on HIV & Pediatrics 2018
Slidesets
Debate: All children should be switched to dolutegravir-based ART regimens PRO- Adeodata Kekitiinwa, MBChB, MMed
Presented at:
International Workshop on HIV & Pediatrics 2018